Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

129.45USD
2:04pm EDT
Change (% chg)

$-0.84 (-0.64%)
Prev Close
$130.29
Open
$129.55
Day's High
$130.25
Day's Low
$129.02
Volume
879,480
Avg. Vol
3,771,006
52-wk High
$139.00
52-wk Low
$96.93

CELG.O

Chart for CELG.O

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.91
Market Cap(Mil.): $101,932.50
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 40.52 78.70 32.82
EPS (TTM): 3.22 -- --
ROI: 10.08 3.22 14.97
ROE: 37.19 5.08 16.21

Grant & Eisenhofer sues for cut of $280 million Celgene settlement

Plaintiffs' law firm Grant & Eisenhofer has sued a former Celgene Corp sales manager and the lawyers who represented her in a whistleblower lawsuit against the drugmaker, claiming it is owed a cut of a recent $280 million settlement in the case.

Aug 14 2017

BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene

* Temasek Holdings (Private) Ltd takes share stake in JPMorgan Chase & Co of 264,337 shares

Aug 14 2017

BRIEF-Celgene Corp says on August 10, co issued $500 million aggregate principal amount of 2.250% senior notes due 2021

* Celgene Corp - on August 10, 2017, co issued $500 million aggregate principal amount of 2.250% senior notes due 2021 - SEC filing Source text - (http://bit.ly/2hNCc4D) Further company coverage:

Aug 10 2017

FDA approves leukemia treatment developed by Celgene, Agios

The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's oral treatment for acute myeloid leukemia (AML) patients with a rare genetic mutation.

Aug 01 2017

UPDATE 2-FDA approves leukemia treatment developed by Celgene, Agios

* Oppenheimer estimates Idhifa sales of $1.4 bln in 2021 (Adds pricing details, analyst comments and share move)

Aug 01 2017

FDA approves leukemia treatment developed by Celgene, Agios

Aug 1 The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's treatment for acute myeloid leukemia (AML) patients with a specific genetic mutation.

Aug 01 2017

Revlimid drives Celgene profit beat; raises EPS forecast

Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday.

Jul 27 2017

UPDATE 3-Revlimid drives Celgene profit beat; raises EPS forecast

July 27 Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday.

Jul 27 2017

Celgene's profit rises 77.4 pct on Revlimid demand

July 27 Celgene Corp reported a 77.4 percent rise in quarterly profit on Thursday, helped by higher sales of its flagship cancer drug, Revlimid.

Jul 27 2017

Celgene to pay $280 million to settle off-label marketing case

The U.S. Justice Department said on Tuesday that Celgene Corp had agreed to pay $280 million to settle a lawsuit that accused the company of promoting its cancer drugs Revlimid and Thalomid for off-label uses.

Jul 25 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,892 +44.00
Eisai Co., Ltd (4523.T) ¥5,555 +8.00
Johnson & Johnson (JNJ.N) $132.98 -1.72
Novartis AG (NOVN.S) CHF80.55 -0.10
Pfizer Inc. (PFE.N) $33.30 +0.15
Roche Holding Ltd. (ROG.S) CHF242.90 -0.10
Roche Holding Ltd. (RO.S) CHF246.90 -0.70
Merck & Co., Inc. (MRK.N) $62.25 -0.17
Sanofi SA (SASY.PA) €81.80 -0.44
AstraZeneca plc (AZN.L) 4,495.00 +61.00

Earnings vs. Estimates